A group of academics is arguing that countries seeking access to a groundbreaking HIV prevention drug from Gilead Sciences ...

Delve into the landscape of biotech companies developing treatments for HIV and find out if we are getting closer to a cure.

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

近日，跨国生物制药巨头吉利德科学（Gilead Sciences）在全球范围内宣布了一系列裁员措施，其中包括将于2025年中终止细胞治疗子公司Kite Pharma在费城的工厂运营。与此相关，吉利德中国的裁员消息也引发了广泛关注。这一消息的背后，究竟隐藏了什么样的市场动态和行业变革？

At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV ...

With that said, let's consider two top dividend stocks that should navigate the current storm relatively well and continue ...

such as HIV-HBV coinfections, know that an epidemic somewhere is an epidemic everywhere.” In the meantime, Somchai, is grateful that he’s been able to do better since those early days when he first ...

We recently published a list of the 11 Most Undervalued Quality Stocks to Buy Now. In this article, we are going to take a ...

The Trump administration's cuts to HIV prevention will lead to new infections, medical costs and death, experts warn.

HIV-HBV coinfection rates can reach 25% in ... Originally published by Gilead Sciences. View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Gilead Sciences' leading HIV business might face a slowdown in 2025, even though a potential approval of lenacapavir would be ...